Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00285324 · ClinicalTrials.gov registry record
Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis
A clinical trial of Primary Brain Tumor and Radiation Necrosis, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- 29
- Enrollment target
- 1
- Study location
NCT00285324 is a study of Primary Brain Tumor and Radiation Necrosis that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 29 participants, below the 82-participant average among 7 other Primary Brain Tumor trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00285324, a study of Primary Brain Tumor and Radiation Necrosis, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the use of a variation of standard magnetic resonance imaging (MRI) called diffusion tensor MRI (DT-MRI) for distinguishing injured brain tissue due to radiation therapy (radiation necrosis) from the return of a brain tumor that was previously removed (tumor recurrence). DT-MRI differs from standard MRI in the way that computers process the images; there is no difference in the experience of having the procedure done. Both radiation necrosis and tumor recurrence can occur within weeks to months following brain radiation treatment. Because the treatment and management options for the two conditions differ significantly, distinguishing the two is of critical importance. Currently, surgical biopsy is required to make this differentiation. Healthy volunteers and patients who have received radiation therapy as part of their treatment for a brain tumor may be eligible for this study. All candidates must be at least 21 years old. Patients must have a new area of abnormality that requires a biopsy to determine whether it is a tumor recurrence or radiation necrosis. Candidates are screened with a medical history and physical examination. In addition, patients have blood and urine tests. All participants undergo MRI and DT-MRI. MRI uses a strong magnetic field and radio waves instead of X-rays to obtain images of body organs and tissues. The MRI scanner is a metal cylinder surrounded by a strong magnetic field. During the MRI, the subject lies on a table that can slide in and out of the cylinder and wears earplugs to muffle loud knocking noises that occur during the scanning. Scanning time varies from 20 minutes to 3 hours, with most scans lasting 40-60 minutes. Subjects may be asked to lie still for up to 20 minutes at a time. DT-MRI is a type of MRI that measures how water moves in the brain tissue. This technique uses the same MRI machine as conventional MRI, but the diffusion images are obtained after the normal MRI scan, and by a computer progra
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2006-01-27 |
| Est. Completion | 2013-08-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00285324
The ClinicalTrials.gov registry entry for NCT00285324 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 82-participant average among 7 other Primary Brain Tumor trials with a reported enrollment target (65% lower). The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Primary Brain Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT00285324 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00285324 about?
NCT00285324 is a clinical study titled "Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis". This study will examine the use of a variation of standard magnetic resonance imaging (MRI) called diffusion tensor MRI (DT-MRI) for distinguishing injured brain tissue due to radiation therapy (radiation necrosis) from the return of a brain tumor that was previously removed (tumor recurrence). DT-M...
What is the current status of trial NCT00285324?
This trial is currently completed. The enrollment target is 29 participants. The study started on 2006-01-27. Estimated completion is 2013-08-20.
What conditions does trial NCT00285324 study?
This clinical trial studies the following conditions: Primary Brain Tumor, Radiation Necrosis, Glioma Tumor Recurrence.
Who is sponsoring clinical trial NCT00285324?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00285324 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
RECRUITING
-
Assessment of Eloquent Function in Brain Tumor Patients
RECRUITING
-
Non-invasive Glioma Characterization Through Molecular Imaging
RECRUITING · NA
-
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
RECRUITING · NA
-
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
RECRUITING · Phase 1
-
Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)
ACTIVE NOT RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.